MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zimmer Biomet Cancels BoneSupport Orders

Swedish orthobiologics company BoneSupport said Zimmer Biomet has canceled most of its orders for the next three months. This follows BoneSupport's earlier decision to set up its own U.S. distribution network and terminate its agreement with Zimmer Biomet.

Swedish orthobiologics company BoneSupport has decided to cut out the middleman and set up its own U.S. distribution network to sell its Cerament bone void filler in the United States.

The Lund, Sweden-based company currently has an exclusive distribution agreement with Zimmer Biomet that is supposed to be in place until Oct. 20, but now that BoneSupport has decided to take control of its commercial platform in the United States, Zimmer Biomet has canceled the major of its orders for a three-month period starting in June.

BoneSupport CEO Emil Billbäck said the company's evaluation of potential distribution partners is "progressing to plan" and that the company expects to have a strong coverage in the U.S. market in place in late October that will position BoneSupport to create a more direct and stronger relationship with its U.S. customer base.

"This enhanced commercial platform will allow us to successfully market our highly differentiated products, particularly Cerament G, which we aim to launch in the U.S. market in 2021," Billbäck said.

Zimmer Biomet retains the right to sell and distribute Cerament bone void filler on an exclusive basis until Oct. 20, and on a non-exclusive basis until April 20, 2019, BoneSupport noted.

For Zimmer Biomet, the news comes as the company is in the throes of a reboot under new CEO Bryan Hanson, who joined the company last December.

500 characters remaining